LLY Eli Lilly and Co
- 849.990
- +12.700+1.52%
- 857.000
- +7.010+0.82%
Eli Lilly and Co News
Krispy Kreme's Stock Soars After Truist Upgrades It to Buy on High Hopes for McDonald's Deal
By Ciara Linnane Stock up nearly 6% premarket as analysts say time to 'indulge in an underappreciated story' Krispy Kreme Inc.'s stock soared 5% early Monday, after Truist upgraded the stock to buy
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $913
Barclays analyst Carter Gould maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $913.According to TipRanks data, the analyst has a success rate of 53.5% and a t
Eli Lilly Study Shows Tirzepatide Superior to Placebo
Eli Lilly and Company (LLY) said Saturday that results from SYNERGY-NASH showed that tirzepatide was superior to placebo for the resolution of metabolic dysfunction-associated steatohepatitis, or MASH
Reported Saturday, Lilly's Tirzepatide Outperformed Placebo In MASH Resolution, With More Than Half Of Patients Showing Fibrosis Improvement At 52 Weeks
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of MedicineINDIANAPOLIS, June 8, 2024 /
The success of K drug cannot be replicated.
Merck CEO Robert Davis believes that the success of K drug cannot be replicated.
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
Lilly's Donanemeb, Remternetug Set to Dominate Alzheimer's Treatment by 2030
Express News | Eli Lilly : Lilly Is Engaged With Regulatory Authorities on the Next Steps for Tirzepatide for the Treatment of Mash
Express News | Lilly's Tirzepatide Was Superior to Placebo for Mash Resolution, and More Than Half of Patients Achieved Improvement in Fibrosis at 52 Weeks
Lilly's Tirzepatide Was Superior to Placebo for MASH Resolution, and More Than Half of Patients...
Lilly's Tirzepatide Was Superior to Placebo for MASH Resolution, and More Than Half of Patients Achieved Improvement in Fibrosis at 52 Weeks
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of MedicineINDIANAPOLIS, June 8, 2024 /
Top 20 turnover | Nvidia's cumulative increase this week exceeded 10%, Gamestop that the "retail investors' leader" is bullish on plummeted nearly 40% in one day.
On Friday, Nvidia recorded the highest trading volume on the US stock market, falling 0.09% with a trading volume of 49.5 billion USD. Apple ranked second with a 1.24% increase and trading volume of 10.4 billion USD. Gamestop, ranked third, experienced a sudden 39.38% drop in closing price with a trading volume of 10 billion USD.
Jim Cramer's Week Ahead: Fed Meeting and CPI Report
CNBC's Jim Cramer on Friday guided investors through next week's most market-moving events, highlighting the Federal Reserve's meeting and the latest consumer price index report. He also mentioned Apple's Worldwide Developers conference and earnings from Oracle, Broadcom and Adobe.
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$150.49 Million in Common Stock
$Eli Lilly and Co(LLY.US)$ 10% Shareholder LILLY ENDOWMENT INC sold 179.62K shares of common stock on Jun 6, 2024 at an average price of $837.815 for a total value of $150.49 million.Source: Announcem
Express News | NYSE Order Imbalance 112395.0 Shares on Sell Side
Catalyst Watch: Apple's WWDC, Tesla's Annual Meeting, Fed's Dot Plot, and GameStop Volatility
Form 144 | Eli Lilly and Co(LLY.US) 10% Stockholder Proposes to Sell 180.02 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Eli Lilly and Co(LLY.US)$ 10% Stockholder LILLY ENDOWMENT INC intends to sell 215K shares of its common stock on Jun 7, with a total market value of approximately $180.
Eli Lilly Is Maintained at Buy by Jefferies
Eli Lilly Is Maintained at Buy by Jefferies
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Express News | Jefferies Financial maintains its buy rating for Eli Lilly and Co (LLY.US) and adjusts the target price from $925.00 to $957.00.
Analysis
Price Target
No Data
